PRINCETON, N.J. / Nov 05, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024.
Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer and Head of Development, and Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer, will take part in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference. They will answer questions about the company beginning at 10:00 a.m. ET on November 11, 2024.
David Elkins, Executive Vice President, Chief Financial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on November 19, 2024. He will answer questions about the company beginning at 9:30 a.m. GMT (U.K.).
Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.
Last Trade: | US$56.79 |
Daily Change: | -0.36 -0.63 |
Daily Volume: | 8,908,400 |
Market Cap: | US$115.270B |
December 23, 2024 December 09, 2024 November 19, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load